Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study

BACKGROUND: Regdanvimab (CT-P59) is a neutralizing antibody authorized in Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who are not on supplemental oxygen and have high risk of progressing to severe disease (age ≥ 50 years or comorbidities). This study evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shinwon, Lee, Soon Ok, Lee, Jeong Eun, Kim, Kye-Hyung, Lee, Sun Hee, Hwang, Soyoon, Kim, Shin-Woo, Chang, Hyun-Ha, Kim, Yoonjung, Bae, Sohyun, Kim, A-Sol, Kwon, Ki Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813598/
https://www.ncbi.nlm.nih.gov/pubmed/35168079
http://dx.doi.org/10.1016/j.intimp.2022.108570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813598/
https://www.ncbi.nlm.nih.gov/pubmed/35168079
http://dx.doi.org/10.1016/j.intimp.2022.108570

Ejemplares similares